Guiding the humoral response against HIV-1 toward a MPER adjacent region by immunization with a VLP-formulated antibody-selected envelope variant

Carolina Beltran-Pavez1,2, Carolina B. Ferreira1,2, Alberto Merino-Mansilla1,2, Amanda Fabra-Garcia1,2, Maria Casadella2,3, Marc Noguera-Julian2,3,4, Roger Paredes2,3,4, Alex Olvera1,2, Isabel Haro5, Christian Brander2,3,4,6, Felipe Garcia1,2, Jose M. Gatell1,2,7, Eloisa Yuste1,2,†, Victor Sanchez-Merino1,2,*

1 AIDS Research Unit, Institut d’Investigacions Biomediques August Pi i Sunyer, Barcelona, Spain, 2 HIVACAT, Barcelona, Spain, 3 IrsiCaixa AIDS Research Institute, Hospital Germans Trias i Pujol, Badalona, Barcelona, Spain, 4 Universitat de Vic-Universitat Central de Catalunya (UVic-UCC), Vic, Spain, 5 Unit of Synthesis and Biomedical Applications of Peptides, IQAC-CSIC, Barcelona, Spain, 6 ICREA, Pg. Lluís Companys 23, 08010 Barcelona, Spain, 7 Infectious Diseases Unit, Hospital Clinic, Barcelona, Spain

These authors contributed equally to this work.
† Current address: Molecular and Cellular Immunology Unit, Institute of Child Health, University College London, London, United Kingdom.
‡ Current address: Medical parasitology department, Radboud University Medical Center. Nijmegen, The Netherlands.
* vmsm70@gmail.com

Abstract

Preventive HIV-1 vaccine strategies rely on the elicitation of broadly neutralizing antibody (bNAb) responses, but their induction in vivo by vaccination remains challenging. Considering that the ability of an epitope to elicit effective humoral immunity depends on its exposure on the virion, we have used a reverse genetics approach to select variants from an HIV-1 AC10_29 randomly mutated envelope library that showed increased affinity for a selected bNAb (4E10 bNAb targeting the HIV-1 MPER region). Isolated envelope sequences were analyzed by deep-sequencing showing a small number of dominant changes, including the loss of four potential N-linked glycosylation sites and disruption of the V1/V2 loop. Accordingly, the dominant variant (LR1-C1), showed not only increased affinity for MPER bNAbs 4E10 and 2F5, but also higher affinity for an additional antibody targeting the V3 loop (447-52D) that could be a consequence of an open conformation tier 1-like Env. Furthermore, the amino acids specific for the selected variant are associated with an increased sensitivity for 4E10 and 2F5 antibodies. In vivo studies showed that sera from mice immunized with LR1-C1 viruses possessed an improved neutralizing activity compared to the wild-type AC10_29 env. While Virus Like Particles (VLPs) carrying this envelope were unable to induce detectable neutralizing activity in immunized rabbits, one animal showed antibody response to the 4E10-proximal region. Our data establish a novel approach that has the potential to yield HIV envelope immunogen sequences that direct antibody responses to specific envelope regions.
Introduction

Many classical vaccine approaches are based on the induction of neutralizing antibodies to surface antigens which often are the most variable portions of the pathogen. In HIV-1 infection, the viral envelope glycoprotein (Env) is the sole virus-specific target of neutralizing antibodies [1–3]. However, Env has evolved several mechanisms to evade or minimize neutralization such as reduced expression on the viral surface, high variability intra and inter-subtypes, glycan coating and steric occlusion [4]. Although these evasion strategies present a major challenge for the induction of neutralizing antibodies by vaccination, it is remarkable that 10–25% of chronically HIV-1 infected individuals show high titers of broadly neutralizing antibodies (bNAbs) with broad neutralizing capacity even against different HIV-1 clades [5–7]. Moreover, it has been reported that up to 50% of HIV-1 infected individuals are able to develop significant plasma neutralization breadth over several years of infection [8]. These studies suggest that the induction of such antibodies generally requires long periods of antigen exposure, which may be a major obstacle for HIV vaccine development. However, work by our lab and by others have described that bNAbs, albeit rare, can be induced much earlier than previously thought, even within the first months of HIV-1 infection [9,10]. Importantly, passive transfer of such bNAbs to humanized mice and monkeys effectively protects them against HIV and chimeric simian-human immunodeficiency virus (SHIV) infection, respectively [11–18]. Furthermore, passively transferred bNAbs have also shown efficacy in controlling viral replication in HIV-1 infected individuals and support the idea that bNAbs might be useful for treatment and prevention of HIV-1 infection [19–22]. This evidence supports the hypothesis that the induction of protective levels of bNAbs by immunization is feasible, if the appropriate immunogens are provided. Thereby, a critical aspect of immunogen delivery is to ensure that the envelope protein is presented in the conformation most appropriate to induce the antibodies of interest. One possible approach to achieve this, which has been shown to be a promising strategy to induce strong immune responses in a safe manner, is immunogen delivery in the context of virus-like-particles (VLPs). VLPs have many advantages as immunogens since they are able to produce protein and lipid self-assembly to generate non-infectious particles mimicking the morphology of wild-type infectious virus. They have also the capacity of presenting native Env trimers on their surfaces and can be presented to T cells in order to mount both humoral and cellular antiviral responses. Currently, there are four VLP-based prophylactic vaccines commercially available such as Human Papilloma virus (HPV), Hepatitis B (HBV), Malaria and Influenza virus. Many others are under clinical or preclinical development supporting this strategy as a promising safe approach to induce strong immune responses [23–25].

Based on these considerations, we decided to take a radically different approach for HIV immunogen design based on the usage of randomly mutated Env libraries. This strategy has been used before for soluble envelope trimers, however, it has not been used for virion incorporated envelopes [26]. Random mutagenesis has been a powerful tool for elucidating protein structure-function relationships and for modifying proteins to improve or alter their characteristics. Sequential rounds of error-prone PCR to introduce random mutations and screening of the resultant mutant libraries have been used to enhance the catalytic activity and the thermal and oxidative stabilities of different enzymes. The approach has also been employed for the identification of drug resistant HIV-1 mutants [27–29]. In the present study, we have applied this strategy to produce and test envelope protein sequences with the potential to better present bNAb epitopes and to elicit in vivo humoral immune responses toward the corresponding epitopes. Our approach is based on the in vitro selection of envelope variants on the surface of viral particles that possess increased affinity for bNAbs using a reverse genetics.
approach. Using this method, we have successfully selected an envelope variant with increased affinity for the broadly neutralizing antibody 4E10 (LR1-C1) that incorporated several amino acid replacements shown to increase sensitivity to neutralization with bNAb 4E10 and 2F5. Moreover, in vivo immunization using VLP-based delivery induced an immune response to a region proximal to the epitope recognized by the antibody used for selection.

**Materials and methods**

**Rapid Immunogen Selection (R.I.S.) method**

Patent applications WO 2012113921 and 2014027082. i) **In-vitro random mutagenesis and subcloning.** Random mutations in the HIV env gene were introduced using a Genemorph II Random Mutagenesis kit (Stratagene, La Jolla, CA) following the manufacturer’s recommendations and using the AC10_29 sequence as the starting template. For mutagenesis, primers 179 and 180 were used (S1 Table). For the generation of a library of chimeric virions, randomly mutated env genes were inserted into pNL4-3 (obtained from the National Institutes of Health AIDS Research and Reference Reagent Program; NIH ARRRP) using convenient restriction sites (XbaI and NotI) to generate replication competent virions. Randomly mutated env genes were also introduced into pcDNA 3.1+ (Invitrogen; Carlsbad, CA, U.S.A.) using XbaI and NotI restriction sites. pcDNA cloning was chosen for library characterization due to its higher cloning efficiency that has, therefore, a minor cloning associated bottleneck. Five independent ligations and transformations were performed simultaneously to avoid the loss of variability and mixed together in the up scaling of amplification. Env-positive clones were sequenced with primers 183, 185, 186, 190, 192 and 193 (S1 Table). ii) **Virion library generation.** Virion library was produced by transfecting the DNA constructions in 293T cells using the calcium phosphate method according to the manufacturer’s recommended protocol (ProFection mammalian transfection system; Promega, Madison, WI). iii) **Virion capture assay.** 96-well plates were coated overnight at 4˚C with 0.5 μg of goat anti-human polyclonal anti-Fc antibodies in PBS. Next, wells were blocked with 3% bovine serum albumin (BSA) in PBS for 1h at 37˚C. Viruses generated from the library were used for selection (20ng of p24) with 4E10 antibody (5 μg/well) for 1h at 37˚C with agitation (450 r.p.m.) in a round bottom 96-well plate, allowing binding to occur. Virus-Ab complexes and a control virus suspension without antibody were then transferred to blocked microtiter wells previously coated with anti-Fc antibodies. After a 2h incubation at 37˚C, wells were washed six times with PBS, and RNA was extracted with High Pure Viral RNA kit by adding the binding buffer directly to the well (Roche, Basel, Switzerland). iv) **Nested RT-PCR HIV-1 env RNA amplification.** Isolated HIV-1 env RNA was then transferred to an Eppendorf tube and, next, it was amplified by reverse transcriptase polymerase chain reaction (RT-PCR). An RNA template was used for the RT-PCR reaction. RNA was reverse transcribed with primer 102 [30]) at 50˚C for 20 min with GeneAmp Gold RNA PCR reagent kit (Applied Biosystems, Waltham, MA, U.S.A.). Env was amplified with the primers 101[30] and 104 [30] from cDNA followed by a nested PCR with primers 179 and 180 (S1 Table) and Expand High Fidelity PCR system (Roche, Basilea, Switzerland). Amplified envs were subcloned and virus stocks were generated as described above.

**Deep-sequencing**

DNA amplification was carried out by a PCR with primers 454_1 and 454_2 for amplicon 1; 454_3 and 454_4 for amplicon 2 and 454_5 and 454_6 for amplicon 3 (S1 Table and S1 Fig). Primers were further ligated with multiple identifier adaptors (MID) specific to the Titanium sequencing chemistry (454/GS/Junior, Roche Diagnostics, Branford, CT). The amplicon library was generated in triplicate followed by pooling and purification of triplicate PCR
products using magnetic beads (Agencourt AMPure Kit, Beckman Coulter Inc., Benried, DE) to eliminate primer-dimers. The number of molecules was quantified by fluorometry (Quant-iT PicoGreen dsDNA assay kit, Invitrogen Corp., Carlsbad, CA, USA). Emulsion PCR (emPCR) was carried out according to the 454 Titanium emPCR protocol (Roche Diagnostics, Branford, CT). The sequencing run was performed on a picotiter plate using the 454/GS/Junior.

Virion-antibody affinity assays

96-well plates were coated overnight at 4 °C with 0.5 μg of goat anti-human polyclonal anti-Fc antibodies in PBS. Next, wells were blocked with 3% bovine serum albumin (BSA) in PBS for 1 h at 37 °C. Serial 2-fold dilutions of recombinant viruses were incubated with the corresponding mAbs (5 μg/well) for 1 h at 37 °C with agitation (450 r.p.m.) allowing binding to occur. The virus-Ab complexes and the control virus suspension with no mAb were then transferred to the blocked microtiter wells previously coated with the immobilized anti-Fc antibodies. Control virus suspension with no mAb showed the background level of non-specific binding. After a 2 h incubation at 37 °C, wells were washed six times with PBS, and virus equivalents were quantified by p24 ELISA. Statistical analysis was conducted by R using One-way NOVA followed by Newman Keuls post hoc test (**p<0.001 and *p<0.05). Data are represented as mean ± SDEV.

Specific envelope amino acid analysis

Gp160 sequences were downloaded from CATNAP database in FASTA format (http://hiv.lanl.gov/catnap) together with IC_{50} values for each antibody-virus pair [31]. The analysis was performed with 675 antibody-virus pairs for 4E10, 676 pairs for 2F5, 144 for 447-52D, 639 for VRC01, 669 for 2G12, 423 for PG16, 255 for PGT151 and 715 for b12. HIV-1 isolates with W503 and N643 amino acids could not be included in the analysis because there was no neutralization data for these isolates in the database. IC_{50} geometric mean of undetected neutralization was set to 100 μg/ml, as described at CATNAP database. Statistical significance was evaluated with a Mann-Whitney U test. Simple comparisons were made with the use of a two-sided alpha level of 0.05.

Optimization of Gag sequence as a T-cell immunogen

An artificial full-length Gag sequence, referred to as dGag was used for the formation of VLP structures. The dGag sequence is based on the 2001 HIV-1 clade B Gag consensus sequence available at the Los Alamos National Laboratory HIV database with modifications at 32 amino acid positions. These sequence changes were introduced to complement our in-house developed T cell immunogen sequence [32] at positions that are frequent targets of the virus-specific CD8 T cell responses (HIV database: https://www.hiv.lanl.gov; [33]) and include residues with more than 10% frequency in the clade B sequence alignment. No changes were introduced in the oligomerization region in p24.

Generation of virus-like particles

HIV-1-dGag-VLPs, composed of the HIV-1 dGag sequence, were produced by transient transfection with the FreeStyle 293 Expression System (Invitrogen, Carlsbad, CA, USA) cotransfecting with a pcDNA-dGag plasmid and codon optimized pcDNA3.1-AC10_29 or pcDNA3.1-LR1C1 envelope expression plasmids provided by GeneArt Gene Synthesis (ThermoFisher Scientific, Waltham, MA, USA). For transfection, 1μg DNA/10^6 cells of each HIV-1
dGag or HIV-1 Env-expression plasmids were used. Different ratios of dGag/Env expression plasmids were tested and 3:1 and 10:1 ratios were chosen for AC10_29 and LR1-C1 VLPs respectively in order to obtain similar Env incorporation for each VLP. At 48 hours post-transfection, VLPs were harvested by ultracentrifugation [34]. Briefly, VLP supernatants were first clarified through centrifugation twice at 800g for 5 min and then ultracentrifugated at 50000g for 32 min. Pellets were ultracentrifuged once more at 160000g for 10 min and resuspended in Trehalose 5%/PBS to preserve VLP integrity and stored at -80˚C [35].

**Immuno-electron cryo-microscopy**

VLPs were produced and ultracentrifugated as described above. VLP pellets were fixed with a 4% paraformaldehyde 0.1% glutaraldehyde solution in 0.1M PB for 1h at 4˚C. Next, the solution was removed carefully and pellets were stored at 4˚C in a 2% paraformaldehyde in 0.1M PHEM at 37˚C and cryo-preserved in 2.3M sucrose in 0.1M PHEM at 4˚C overnight. Then, they were mounted in pins and frozen in liquid nitrogen. Ultrathin sections were obtained in a FC7 ultramicrotome (Leica Microsystems, Wetzlar, Germany) and were immunolabeled with an anti-gp120 antibody (447-52D; Polymun Scientific, Klosterneuburg, Austria) and a gold-conjugated anti-human antibody (Jackson Immunoresearch, West Grove, PA, USA). Samples were visualized in a Transmission Electron Microscopy (TEM) Tecnai Spirit (FEI) at 120 kV with a LaB6 cathode and equipped with a 1kx1k Megaview CCD Camera.

**Western blotting**

Env incorporation per virion or per VLP was analysed by western blotting in SDS-PAGE gels. Identical quantities of p24 or p55 were mixed with Laemmli buffer supplemented with 5% β-mercaptoethanol, boiled for 10 minutes and kept on ice. Env expression in 293T cells was also analysed by western blotting after lysing with a Cell lysis buffer (Cell Signaling Tecnology, Danvers, MA, U.S.A) and boiled for 10 minutes. Samples were then electrophoresed at 160V for 90 minutes through a 4 to 12% polyacrylamide-sodium dodecyl sulfate gradient gel (GE Healthcare, Chicago, IL, USA). Following electrophoresis, proteins were transferred in a semi-dry system onto a PVDF membrane for 45 minutes at 0,1mA. Membranes were blocked with 5% skim milk in Tris-buffered saline tween 20 (TBST) for 1h at room temperature. Membranes were then incubated with antibodies recognizing the gp120 (447-52D provided by the NIH AIDS Research and Reference Reagent Program), Gag (p24 and p55) [p24 Antibody (24–4); Santa Cruz Biotechnology, Santa Cruz, CA, USA] and β-actin [β-Actin (13E5) Rabbit mAb; Cell Signaling Technology, Danvers, MA, U.S.A.). A goat anti-human-HRP (SC-2907; Santa Cruz Biotechnology, Santa Cruz, CA, USA) was used to detect gp120. Finally, Env and Gag proteins were detected with Clarity Western ECL (Bio-rad, Hercules, CA, USA) using the ImageQuant LAS 500 imager (GE Healthcare, Chicago, IL, USA). Quantitative western blot was performed as described previously [36] with a standard curve of p24 recombinant protein (HIV-1/NL43 p24 capsid p1M) to quantify p55 in VLP samples. The presence of trimers was analysed by western blotting in BN-PAGE gels as described previously [37]. VLPs were solubilized at room temperature for 10 min in 0.12% Triton X-100 in 1mM EDTA-1.5 aminocaproic acid with 1μl of protease inhibitor cocktail (Sigma-Aldrich, St. Louis, MO, USA) at 1:1 ratio. The sample buffer used was 100mM MOPS, 100mM Tris-HCl pH: 7.7, 40% glycerol and 0.1% coomassie Blue G250 added at 1:1 ratio. Samples were loaded onto 4–12% Bis-Tris NuPAGE (Invitrogen, Carlsbad, CA, USA) separated for 3h at 100V at 4˚C using High Molecular Weight calibration kit for native electrophoresis (Amersham, Buckinghamshire, UK) as a size standard. Proteins were blotted in a wet tank onto a PDF membrane at 4˚C and 30V overnight. Then, membranes were blocked with 4% nonfat milk/PBS buffer for 1 hour at room
temperature and stained with an anti-gp120 and anti-gp41 antibody cocktail (MAbs 2G12, b12, 39F, 2F5, 4E10 and 447-52D at 1μg/ml each one) overnight at 4˚C. Finally, membranes were washed 3 times with PBS, probed by an anti-human-HRP (Jackson ImmunoResearch, West Grove, CA, USA) and proteins were detected by Pierce ECL Western Blotting Substrate (Thermo Fisher Scientific, Waltham, MA, USA).

**Immunization of BALB/c mice**

The viral stocks used for immunization were obtained by transient transfection in 293T cells as described above. Viral stocks were inactivated by incubation with Aldritiol-2 1mM at 37˚C for 2h under continuous agitation. Female BALB/c mice aged 6 to 8 weeks and specific pathogen free (SPF) were utilized. Mice were fed ad libitum with a standard diet and kept under a light-dark cycle of 12h. Each group was composed of 5 animals. Both groups were inoculated with 100μl of AT-2 inactivated virus (2.5μg/ml p24 quantified as explained above) and 100μl of complete Freund adjuvant subcutaneously divided among all 4 legs (t = 0). Two weeks later (t = 14 days), mice were inoculated with 100μl of AT-2 inactivated virus (2.5μg/ml p24) and 100μl of incomplete Freund adjuvant subcutaneously into each leg. After two weeks (t = 28 days), between 400μl and 1ml of blood were extracted by cardiac puncture under isoflurane anesthesia from both groups. Mice euthanasia was performed by overdose of isoflurane. One subject from the first group perished before conclusion of the four weeks for reasons not related to the experimental protocol (S4 Fig). These experiments were performed in a BSL3 Biocontainment Facility at Centre de Recerca en Sanitat Animal (CReSA) with the support by CReSA staff (Barcelona, Spain).

**Rabbit immunizations**

5 groups of rabbits were immunized (4 per group): HIV-1-Gag-VLPs as a control group (G1); HIV-1-Gag-VLPs with AC10_29 Env (G2/G4) and LR1-C1 Env (G3/G5). In G1-G3 groups Adjuplex adjuvant (Sigma-Aldrich, St. Louis, MO, USA) was used while no adjuvant was added in groups G4 and G5. The vaccination protocol used was a DNA prime followed by one DNA boost (500μg of DNA/boost/animal) and 3 VLP boosts (20μg of p24 of VLP/boost; S5 Fig). 15 weeks after immunization, the presence of anti-HIV-1 antibodies was analyzed using New Lav Blot I kit (Bio-Rad, Hercules, CA, USA) substituting the horseradich peroxidase-conjugated for a alkaline phosphatase-goat anti-rabbit IgG (Invitrogen, Carlsbad, CA, USA) diluted 1/1,000 in 5% milk in PBS. All rabbits were maintained in 785 x 840 x 1840 h (mm) cages with access to water and food ad libitum and under constant humidity and temperature with a light/dark cycle of 12 hours. All procedures were conducted in accordance with the guidelines established by the University of Barcelona’s Bioethics Committee, as stated in Law 214/97 (July 30th) drawn up by the Generalitat de Catalunya.

**Enzyme-linked immunoabsorbent assays (ELISA)**

Wells of 96-well high-binding plates (Inmulon, ThermoFisher Scientific, Waltham, MA, USA) were coated with 100μl of AC10_29 (HIV-1, clade B; gp120; Abnova, Tipei, Taiwan) at 200ng/well with phosphate-buffered saline (PBS) and incubated at 4˚C overnight. Next, wells were blocked with 150μl of 5% nonfat powdered milk in PBS at 37˚c for 1h. 100μl of the corresponding sera dilutions in 5% PBS-milk were added to each well and incubated at 37˚C for 1h. After washing three times with PBS plus 0.05% Tween 20, 100μl of horseradich peroxidase-conjugated goat anti-rabbit immunoglobulin G antibody (sc-2004, Santa Cruz Biotechnology, Santa Cruz, CA, USA) diluted 1/2,000 in 5% milk in PBS was added to each well, and the plates were incubated at 37˚C for 1h. Plates were then washed 6 times with PBS-Tween, and 100μl of
tetramethylbenzidine reagent (Calbiochem, San Diego, CA, USA) was added to each well. 10 minutes later, 50μl of hydrochloric acid was added to each well, and optical density at 450nm was measured using a spectrophotometer (Sunrise, TECAN, Zürich, Switzerland). For Env peptide ELISA, 15-mer peptides corresponding to the V3 loop and the gp41 ectodomain of AC10_29 Env sequence (283 to 341 amino acids and 629 to 686 respectively, numbered according to HXB2) were synthesized by Bionova (V3 peptides; Bionova, Halifax, Canada) and by the Unit of Synthesis and Biomedical Applications of Peptides, IQAC-CSIC, Barcelona (gp41 peptides). The assay was performed as described previously [38].

Neutralization assays

400 μl of sera from immunized mice and rabbits were pre-adsorbed with 1x10^6 cells that were used for virus or VLP production (293T and 293F respectively) for 1h at room temperature with rotation. Next, IgGs purified from pre-adsorbed immunized animal sera were purified with prot A columns (GE Healthcare, Chicago, IL) and tested against a panel of 6 recombinant viruses from five different subtypes as described previously [39].

Statistics. For virion capture assays, statistical analysis was conducted by R using One-way NOVA followed by Newman Keuls post hoc test (***p<0.001 and *p<0.05). For the comparison of neutralization sensitivities to several bNabs of viruses from neutralization HIV-1 database (http://hiv.lanl.gov/catnap) with any of the amino acid replacements incorporated by LR1-C1, statistical significance was evaluated with a Mann-Whitney U test. Simple comparisons were made with the use of a two-sided alpha level of 0.05. Endpoint ELISA titers were also evaluated with a Mann-Whitney U test and simple comparisons were also made with the use of a two-sided alpha level of 0.05.

Results

Generation and characterization of a randomly mutated envelope library (L)

The objective of this study was the selection of Env variants with increased exposure of epitopes recognized by bNab 4E10. This is an early antibody candidate that was available at the time of initiating selection experiments and humoral immunity to its targeted region had been associated with broad antiviral activity [40]. AC10_29 envelope from a clade B, tier 2 primary isolate was selected as the template for generating the randomly mutated library. AC10_29 was chosen for being a tier 2 primary isolate from a recently infected patient [41]. Tier 2 neutralization phenotype has been associated to closed Env trimer configuration that is believed to be more relevant for vaccination and is typical of most circulating strains [42]. AC10_29 overall neutralization profile against a group of bNAbs, including 4E10, is shown in S2 Table and our data are consistent with the data available at the CATNAP database (http://hiv.lanl.gov/catnap) [31]. Random mutagenesis was performed in the env gene by a PCR based method with conditions chosen in order to generate a mutation frequency of approximately 10^-3 substitutions per nucleotide (Fig 1A). To monitor the mutations accumulated during random mutagenesis, the library (L) was cloned into pcDNA 3.1+ and the full-length env genomic nucleotide sequence from 15 clones was determined (Table 1). The frequencies of each mutation ranged between 22.3% for G→A and 1.5% for A→C. Non-synonymous mutations represented 47% of the total changes introduced. An insertion of one nucleotide and three single nucleotide deletions were also observed among the 15 clones (Table 1). In summary, 215 mutations were found (median; 14.33 and ranging from 3 to 21 mutations per env gene). Overall, mutation frequency in the library (L) was 5.5x10^-3 substitutions per nucleotide calculated by comparison with the consensus sequence that matches AC10_29 and changes were randomly distributed throughout the env gene.
Selection of an HIV envelope immunogen that directs antibody responses toward the MPER proximal region

A. Random mutagenesis

B. Transient transfection in 293T cells

C. Virion capture assay

D. p24 quantification

E. Cloning

env library after 1st round of selection

env gene RT-PCR amplification
Deep-sequencing analysis was used to characterize the library (L) in more detail, as previously described [43]. More than 9,000 454-sequence reads were obtained for each of the 3 amplicons generated from the parental clone and the library (S1 Fig). Considering the 454 sequencing error profile, diversity analysis was performed by counting non-reference nucleobases per nucleotide position on a reference-guided pair wise alignment. Positional diversity, defined as the frequency of all non-reference nucleobases at each position, for the parental clone was invariably below 0.3% except in two neighboring positions located in a homopolymeric region, which showed values around 0.6% (Fig 2A). Positional diversity analysis of the library (L) confirmed a random distribution of mutations in the dataset with no positional diversity higher than 3% (Fig 2B). The frequencies of each type of mutations observed by deep-sequencing were very similar to the frequencies obtained by standard sequencing (Table 1A and 1B). The only significant differences between standard and deep-sequencing analysis were the frequencies of T → G mutation (5.6% vs. 0.0%) and C → T (5.1% vs. 21.1%) (Table 1A and 1B). To determine whether the differences observed in both analyses could be attributed to the different regions sequenced by both methods (the full-length env gene for the standard sequencing and the regions corresponding to the three amplicons for deep-sequencing; S1 Fig), we compared the sequences only in the regions corresponding to the indicated deep-sequencing amplicons and similar results were observed (S3 Table). For this reason we believe that the observed differences could be attributed to cloning efficiency or to the limited number of clones analyzed by standard sequencing. In future studies we will increase the size of the sequenced library to address this issue.

**Mutation accumulation as result of selection of HIV-1 envelope mutants using 4E10 as bait with the Rapid Immunogen Selection method (R.I.S.)**

To determine which mutations accumulated after 4E10 selection out of the randomly mutated env library (L), the 4E10 selected library (4E10sL) was cloned into pcDNA3.1+ and the full-length env genomic nucleotide sequence from 7 clones was determined. Mutation frequencies

| Mutations | Standard sequencing | Deep-sequencing |
|-----------|---------------------|-----------------|
| L (%)a    | 22.3 7.9 4.2 13.0 7.9 1.5 8.8 13.0 5.6 6.5 5.1 2.3 1.5 0.4 |
| 4E10sL (%)b | 11.7 9.6 2.1 13.8 26.6 0.0 5.3 6.4 3.2 11.7 6.4 0.0 3.2 0.0 |
| L (%)b     | 19.4 6.6 1.4 12.1 6.4 1.6 11.6 11.7 0.0 3.7 21.1 3.4 0.9 0.0 |
| 4E10sL (%)b | 13.9 5.6 6.3 21.4 19.1 3.2 7.0 12.7 1.8 2.5 5.8 0.7 0.0 0.0 |

a The env nucleotide sequence of 15 clones from the initial library (L) and 7 clones from the library after one round of R.I.S. selection with 4E10 monoclonal antibody (4E10sL) was determined as described in Materials and Methods section. The percentages are calculated over the total number of mutations.

b More than 9,000 sequence reads were obtained for each of the 3 amplicons generated (S1 Fig) from both the initial library (L) and the library after one round of R.I.S. selection with 4E10 monoclonal antibody as described in Materials and Methods section. The percentages are calculated over the total number of mutations.

a Nucleotide deletions

b Nucleotide insertions.
ranged between 26.6% for A→G and 0.0% for A→C and C→G; Non-synonymous mutations represented 90.4% of the total, in contrast to what was observed in the initial library (47%), which suggests a strong selection force by 4E10 selection. Three single nucleotide deletions were also observed (Table 1). In summary, 79 mutations were found (median: 11.29 and ranging from 8 to 22 mutations per env gene analyzed). Overall, mutation frequency in the library after 4E10 selection (4E10sL) was 4.3 x10^{-3} substitutions per nucleotide calculated by comparison with the corresponding parental sequence (AC10_29). Standard sequences have been deposited in GeneBank (accession numbers MK034104 to MK034126).

Next, a deeper analysis of the selected library (4E10sL) was carried out by deep-sequencing. 4E10 antibody-selected env sequences showed a significant increase of specific mutations compared to the initial clone that was used as template (Fig 2C). Deep sequencing experimental design was adapted to preliminary standard sequencing that revealed major differences in the deep-sequenced regions. Deep Sequencing rawdata have been deposited in CBI/SRA.

Fig 2. Positional diversity detected by deep-sequencing in parental virus AC10_29 (A) and the mutant library before [L; (B)] and after selection by the R.I.S. method [4E10sL; (C)]. (A) Amplicon sequencing of the original primary isolate before random mutagenesis of the env gene revealed a homogeneous population. (B) The library generated by random mutagenesis had a wide variability of mutations across the amplicons sequenced. (C) Some mutations are fixed after selection with 4E10 by the R.I.S. method. Positional diversity is calculated as the frequency of all nucleotides that differ from the parental strain (AC10_29) at each evaluated position. Insertions and deletions are taken into account. Genomic regions corresponding to each amplicon are indicated.

https://doi.org/10.1371/journal.pone.0208345.g002
repository with accession PRJNA495005. Most of the amino acid replacements observed in the library after selection (4E10sL) with frequencies above 5% are apparently well tolerated by the envelope protein, as indicated by the acceptability value (Table 2). The degree of acceptability of the amino acid substitution follows the criteria described in Feng et al. where interchanges are more likely to happen between amino acids that have similar chemical structures [44]. The acceptability scale ranges from 0 to 6, with the latter value representing replacement by the

Table 2. Amino acid replacements in AC10_29 parental sequence with frequencies above 5% observed in the envelope library after 4E10 R.I.S. selection (4E10sL).

| Env amino acid change | Frequency in 4E10sL (%) | Acceptability | Location | Frequency in HIV-1 Database |
|-----------------------|-------------------------|---------------|----------|----------------------------|
|                       |                         |               |          | (LANL HIV-1 ENV AMINO ACID WEB; n = 6223 amino acid sequences) |
| E87G                  | 17.8                    | 4             | C1       | E: 54.44%; G: 15.15%; other: 30.41% |
| N88D                 | 27.8                    | 5             | C1       | N: 99.21%; D: 0.28%; other: 0.79% |
| V89L                  | 20.6                    | 5             | C1       | V: 98.18%; L: 0.24%; other: 1.58% |
| C131Y                 | 16.3                    | 3             | V1       | C: 99.65%; Y: 0.03%; other: 0.32% |
| T132N                 | 16.2                    | 4             | V1       | T: 61.10%; N: 3.68%; other: 35.22% |
| N137D                 | 7.8                     | 5             | V1       | T: 33.49%; N: 31.98%; D: 3.21%; other: 31.32% |
| D138G                 | 16.5                    | 4             | V1       | N: 27.27%; G: 5.08%; D: 3.82%; other: 63.83% |
| D138Y                 | 6.1                     | 2             | V1       | N: 27.27%; D: 3.82%; Y: 1.47%; other: 67.44% |
| T141S                 | 16.4                    | 5             | V1       | N: 27.66%; T: 25.50%; S: 13.66%; other: 33.18% |
| F159Y                 | 5.5                     | 5             | V2       | F: 96.88%; Y: 2.79%; other: 0.33% |
| N160Y                 | 17.0                    | 3             | V2       | N: 92.96%; Y: 0.91%; other: 6.13% |
| M165L                 | 14.9                    | 5             | V2       | I: 46.42%; L: 33.01%; M: 4.19%; other: 16.38% |
| Q172H                 | 16.2                    | 4             | V2       | E: 42.84%; Q: 3.41%; H: 0.06%; other: 53.69% |
| N187D                 | 16.3                    | 5             | V2       | N: 44.42%; D: 16.46%; other: 39.12% |
| S188R                 | 5.6                     | 3             | V2       | Insertion amino acid R; not applicable |
| S195C                 | 6.9                     | 4             | V2       | N: 67.72%; S: 25.17%; C: 0.04%; other: 7.07% |
| I213F                 | 5.4                     | 4             | C2       | I: 99.11%; F: 0.09%; other: 0.8% |
| Y217F                 | 14.6                    | 5             | C2       | Y: 96.05%; F: 3.05%; other: 0.90% |
| A219V                 | 13.5                    | 5             | C2       | A: 77.03%; T: 22.35%; V: 0.36%; other: 0.26% |
| A433T                 | 6.2                     | 5             | C4       | A: 98.30%; T: 0.17%; other: 1.53% |
| S440G                 | 10.8                    | 5             | C4       | A: 28.06%; S: 14.41%; G: 0.41%; other: 57.12% |
| N462H                 | 8.1                     | 4             | V5       | N: 63.55%; S: 12.35%; H: 0.20%; other: 34.90% |
| Q464E                 | 8.4                     | 4             | V5       | T: 27.56%; E: 11.00%; Q: 3.04%; other: 58.40% |
| E466V                 | 18.2                    | 4             | V5       | E: 96.38%; Y: 0.30%; other: 3.32% |
| G472E                 | 8.9                     | 4             | C5 (CD4 contact) | G: 99.80%; E: 0.04%; other: 0.16% |
| M475I                 | 13.6                    | 4             | C5 (CD4 contact) | M: 90.87%; I: 8.45%; other: 0.67% |
| R500T                 | 11.5                    | 3             | C5       | K: 49.77%; R: 23.93%; T: 3.65%; other: 22.65% |
| R503W                 | 15.4                    | 2             | C5       | R: 99.61%; other: 0.39%; NO Ws |
| K510N                 | 8.4                     | 4             | C5       | K: 97.80%; other: 2.20%; NO Ns |
| S534T                 | 26.2                    | 5             | gp1(HR1) | S: 96.43%; T: 0.032%; other: 3.53% |
| V539I                 | 7.1                     | 5             | gp1(HR1) | V: 95.02%; I: 0.04%; other: 4.94% |
| L555P                 | 7.9                     | 3             | gp1(HR1) | L: 99.12%; other: 0.88; NO Ps |
| T569I                 | 5.4                     | 3             | gp1(HR1) | T: 98.47%; other: 1.53%; NO Is |
| K574M                 | 23.9                    | 2             | gp1(HR1) | K: 98.81%; other: 1.19%; NO Ms |
| Q590P                 | 8.8                     | 3             | gp1(HR1) | Q: 99.58%; P: 0.032%; other: 0.38% |
| S618T                 | 5.7                     | 5             | gp1(HR2) | S: 76.31%; T: 16.79%; other: 6.90% |

(Continued)
same amino acid. Only 3 out of the 37 amino acid replacements observed with a frequency above 5% (D138Y, R503W and K574M) have an acceptability value below 3, supporting the notion of poorly accepted mutations. It is important to note that one third of the mutations enriched to above 5% frequency after selection were located in the gp120 V1 and V2 variable loops (Table 2).

To create virions carrying selected env sequences after 4E10 selection, the library 4E10sL was subsequently cloned into the pNL4-3 backbone and sequenced. Sequence analysis of the resulting clones revealed that one of the clones, LR1-C1, incorporated a total of 10 amino acid replacements which were present in more than 10% (none of the amino acid replacements were present in a frequency below 10%) of sequences isolated after 4E10 selection (Table 2; LR1-C1 mutations are indicated). It is noteworthy that most amino acid replacements incorporated by LR1-C1 are rare according to their frequency in the HIV database (Table 2). 5 of these amino replacements (50%) were located in the gp120 V1/V2 loop. Mutation C131Y is especially relevant because this substitution eliminates the native disulfide bond between C131 and C157, thereby disrupting the architecture of the V1/V2 loop. Importantly, among the mutations incorporated in LR1-C1, there is a loss of 4 potential N-linked glycosylation sites: N88D, N137D, N160Y and N187D (Asn-X-Ser/Thr, where X can be any amino acid).

### Table 2. (Continued)

| Env amino acid change | Frequency in 4E10sL (%) | Acceptability | Location | Frequency in HIV-1 Database (LANL HIV-1 ENV AMINO ACID WEB; n = 6223 amino acid sequences) |
|-----------------------|------------------------|---------------|----------|----------------------------------------------------------------------------------|
| Y643N                 | 12.1                   | 3             | gp41(HR2) | Y:98.15%;other:1.85%; NO Ns |

*a*Amino acids are numbered according to the numbering for isolate HXB2.

*b*Replacements corresponding to LR1-C1 clone are shaded.

*c*Frequency of clones observed with each mutation out of the 9,000 sequence reads obtained for each of the 3 amplicons amplified from the library obtained after R.I.S. selection.

*d*The degree of acceptability of the amino acid substitution is given according to reference (42); the acceptability scale is from 0 to 6 with the latter value representing replacement by the same amino acid.

*e*Location of amino acid replacements is based on Los Alamos Database (www.hiv.lanl.gov)

*f*Amino acid alignments representing the fullest spectrum of sequences in Los Alamos Database (www.hiv.lanl.gov)

*g*Potential N-linked glycosylation sites.

https://doi.org/10.1371/journal.pone.0208345.t002

same amino acid. Only 3 out of the 37 amino acid replacements observed with a frequency above 5% (D138Y, R503W and K574M) have an acceptability value below 3, supporting the notion of poorly accepted mutations. It is important to note that one third of the mutations enriched to above 5% frequency after selection were located in the gp120 V1 and V2 variable loops (Table 2).

To create virions carrying selected env sequences after 4E10 selection, the library 4E10sL was subsequently cloned into the pNL4-3 backbone and sequenced. Sequence analysis of the resulting clones revealed that one of the clones, LR1-C1, incorporated a total of 10 amino acid replacements which were present in more than 10% (none of the amino acid replacements were present in a frequency below 10%) of sequences isolated after 4E10 selection (Table 2; LR1-C1 mutations are indicated). It is noteworthy that most amino acid replacements incorporated by LR1-C1 are rare according to their frequency in the HIV database (Table 2). 5 of these amino replacements (50%) were located in the gp120 V1/V2 loop. Mutation C131Y is especially relevant because this substitution eliminates the native disulfide bond between C131 and C157, thereby disrupting the architecture of the V1/V2 loop. Importantly, among the mutations incorporated in LR1-C1, there is a loss of 4 potential N-linked glycosylation sites: N88D, N137D, N160Y and N187D (Asn-X-Ser/Thr, where X can be any amino acid).

#### 4E10 selected mutations incorporated by LR1-C1 increased virion affinity for 4E10, 2F5 and 447-52D monoclonal antibodies

The affinities of LR1-C1 variant for selected monoclonal neutralizing antibodies were compared to the parental virus (AC10_29) using a virion capture assay. The assay was performed in triplicate for each antibody at each virion concentration (Fig 3). The data showed an increased affinity of LR1-C1 virions for 4E10, 2F5 and 447-52D antibodies compared to the parental virus. A statistically significant increase in affinity was also observed for antibody 2F5 only at the highest input concentration (p<0.001). Noteworthy, a statistically significant affinity increase was also observed for antibody 4E10 at two input concentrations (p<0.001) confirming the efficacy and specificity of the selection process. As confirmation of this result we have observed that LR1-C1 also has increased affinity for antibody 10E8 that is specific for the same epitope (S3 Fig). Additionally, a significant increase was observed for 447-52D at two input concentrations (p<0.05 and <0.001 respectively). The increased affinity of 4E10 selected virions for the 2F5 antibody is consistent with the close proximity in which the two antibody
epitopes are located inside the gp41 membrane proximal domain. These affinity increases are also in line with several reports that correlated the loss of glycosylation sites and the disruption of the V1-V2 loop architecture with an increased sensitivity to antibody mediated neutralization [38,45–52]. The increase in the affinity for 447-52D, whose epitope is located in the V3 loop, is also consistent with previous reports that showed the masking of V3 by the V1-V2 loop [53–57]. However, the increased binding by 447-52D suggests that LR1-C1 Env may have changed to an open tier 1-like conformation [58]. The affinities for VRC01 and 2G12, in contrast, decreased compared to AC10_29 and no binding to PG16 and PGT151 was observed for the LR1-C1 variant. The lack of binding to PG16 and PGT151 could be attributed to mutations at positions 160 and 503 respectively that have been previously associated to this effect [59,60]. The decreased exposure of additional epitopes, such as VRC01, 2G12, PG16 and PGT151, that
could also be relevant for the induction of broadly neutralizing antibodies could be an undesired side effect associated with the selection process. The low affinity of LR1-C1 to quaternary-structure dependent antibodies, such as PG16 and PGT151, suggests that LR1-C1 envelope may be inefficient forming trimers. No differences in the affinity for 5F3 antibody (non-neutralizing; gp41 C34 helix) were observed. 

Amino acids incorporated by LR1-C1 are associated with increased sensitivity to 4E10 and 2F5 antibodies in HIV-1 isolates described in the Los Alamos database

First of all we wanted to determine the association of 4E10 selected amino acids with increased neutralization sensitivities to selected monoclonal antibodies by TZM-bl assays. Unfortunately, this analysis could not be done because LR1-C1 was not infectious in TZM-bl cells (S2 Fig). As an alternative approach, we compared the corresponding IC$_{50}$s between viruses that had one or more of the amino acid replacements incorporated by LR1-C1 (Table 2) and viruses that did not contain any of those amino acids in HIV-1 isolates from Los Alamos database. Our analyses showed that the IC$_{50}$ titer of 4E10 and 2F5 antibodies were significantly higher among the virus group with one or more LR1-C1 amino acids compared to the group with no LR1-C1 amino acids (p < 0.005 and p < 0.0001 respectively; Fig 4). However, IC$_{50}$ titers of 447-52D, VRC01, 2G12, b12, PG16 and PGT151 did not significantly differ between the
virus groups with one or more LR1C1 amino acids or no LR1-C1 amino acids (Fig 4). HIV-1 isolates with Y131, W503 and N643 amino acids were not included in the analysis because there were no isolates with these amino acids or no neutralization data in the database.

Effects of mutations incorporated after 4E10 selection on envelope incorporation in virions

Next, we assessed the extent to which mutations incorporated by LR1-C1 affected incorporation of envelope proteins into virions. To this end, infectious virus was produced in 293T cells, chemically inactivated with AT-2 and pelleted from clarified supernatants. Virion samples were then subjected to analysis by Western blot (Fig 5A). This analysis revealed a significant amount of virions with incomplete processing of Gag precursors evidenced by the presence of p55 and p41 Gag proteins. This effect could be attributed to the AT-2 treatment considering
that inhibitors of HIV-1 zinc fingers prevent normal processing of Gag precursors [61]. In addition, we determined the Env to Gag (p55+p41+p24) ratio in virions carrying the 4E10-selected envelope, LR1-C1, relative to the AC10_29 by densitometry (Fig 5B). This analysis revealed that LR1-C1 envelope was incorporated into virions at higher levels than AC10_29 (2.7-fold increase; Fig 5). Finally, Env expression in 293T virion producer cells was analyzed and showed a 2-fold increase in Env expression per cell that could be, at least in part, responsible for the greater Env incorporation in LR1-C1 virions (Fig 5C and 5D).

4E10-selected envelope variant (LR1-C1) increases the neutralization capacity of the humoral response induced in BALB/c mice

Changes in the humoral immune response following immunization with the AC10_29 wild type or the LR1-C1 variant were evaluated in mice vaccinated with AT-2 inactivated virions. AT-2 inactivation was chosen over heat-inactivation because this procedure better preserves Env three-dimensional structure [62]. In order to deplete the sera of vaccinated animals from the antibodies generated against cellular components present in virions (from 293 producer cells), sera from immunized mice were pre-adsorbed against 293T cells. In order to minimize the background, IgGs were purified from immunized mice and were tested against a VSV pseudotyped HIV-envelope deficient control. Purified IgG fractions were then tested for neutralizing activities against two different HIV-1 strains (NL4-3, tier 1 and AC10_29, tier 2). Assays were run in triplicate at a 0.2mg/ml IgG concentration and neutralization results are shown in Table 3. IgGs purified from mice immunized with LR1-C1 showed a moderately improved neutralization breadth compared to the AC10_29 immunized mice. Three out of the five sera were capable of neutralizing AC10_29 and one of them could also neutralize NL4-3. In contrast, only one mouse of the 5 animals immunized with AC10_29 neutralized AC10_29 virus with no neutralization of NL4-3 at all. IgG purified from immunized mice sera showed no neutralization of the VSV pseudotyped virus used as specificity control. Due to limited sample size, insufficient purified IgGs were obtained from immunized mice and complete neutralization curves could not be performed. Therefore, IC50 values could not be determined and further neutralization testing of against additional HIV isolates and epitope mapping could not be performed.

4E10-selected envelope variant (LR1-C1) increases immunogenicity of the 4E10-proximal region in rabbits

To further evaluate the humoral immune response induced by the 4E10-selected envelope, rabbits were immunized with HIV-1-Gag virus like particles carrying AC10_29 and LR1-C1 envelope variants. VLPs were generated using the dGag sequence and each envelope sequence as indicated in the Materials and Methods section. Cryo-immuno Transmission Electron Microscopy (TEM) was conducted to analyze VLPs produced from 293F cells that had been

Table 3. Neutralization of AC10_29 and LR1-C1 immunized mice.

|                  | AC10 immunized mice | LR1-C1 immunized mice |
|------------------|----------------------|------------------------|
|                  | 1  | 2  | 3  | 4  | 1  | 2  | 3  | 4  | 5  |
| VSV pseudotyped  | 8.2±5.6 | 11.1±11.2 | 0.0±10.7 | 15.0±4.2 | 7.6±16.3 | 0.0±6.1 | 3.6±1.5 | 0.0±11.2 | 0.0±16.5 |
| NL4-3            | 0.0±0.5 | 3.0±25.8 | 0.0±18.9 | 33.3±30.1 | 58.8±14.6 | 0.0±11.7 | 0.0±41.5 | 0.0±28.3 | 33.6±17.3 |
| AC10             | 13.9±23.7 | 47.0±3.7 | 47.3±5.7 | 60.0±3.8 | 63.8±1.8 | 32.9±9.6 | 65.0±10.9 | 44.3±5.4 | 54.7±5.2 |

Numbers indicate percent neutralization ± standard deviation. A white box indicates <50% neutralization and a yellow box indicates >50% neutralization.

https://doi.org/10.1371/journal.pone.0208345.t003
transiently transfected with Gag and Env expression vectors as indicated in the Materials and Methods section. Immuno-electron cryo-microscopical analysis revealed that VLPs were spherical with electron density below the VLP membrane. In addition, VLPs resulted in particle sizes around 130nm in diameter and envelope incorporation was verified by 447-52D labeling (Fig 6A). The amount of labeling per VLP was scarce, as is expected of HIV envelope proteins with untruncated gp41 cytoplasmic tails [63]. Transfection conditions were adapted to ensure that both VLPs had similar amounts of envelope incorporated and was verified by western blotting (Fig 6B). The presence of either envelope trimers incorporated into VLPs and was confirmed by BN-page (Fig 6C) showing comparable levels of AC10_29 and LR1-C1 in these VLP preparations.

Rabbits were immunized with VLPs carrying AC10_29 and LR1-C1 envelopes with and without adjuvant (G2: AC10_29 with adjuvant; G3: LR1-C1 with adjuvant; G4: AC10_29 with no adjuvant and G5: LR1-C1 with no adjuvant). Adjuvanted HIV-1-Gag VLPs with no envelope incorporated were used as controls (G1). All rabbits immunized with AC10_29 and LR1-C1 HIV-1-Gag-VLPs developed responses to HIV-1 Gag and Env HIV-1 proteins (Fig 7). Responses to monomeric rgp120 were more potent to both autologous and heterologous rgp120 when Adjuplex was used for immunization (G2/G3; Fig 7B and Fig 7C). In addition, the gp120 responses were slightly higher in the LR1-C1-immunized group compared to the AC10_29 immunized group only with autologous gp120 but these differences were statistically significant only in the groups immunized with no adjuvant. All 8 sera from G2 and G3 rabbits showed antibody responses to the gp120 V3 loop (Fig 8A) and one of the rabbits immunized with LR1-C1 HIV-1-Gag-VLPs (1650) developed an antibody response to a region in close proximity to the 4E10 epitope (18 amino acids upstream; Fig 8B, specifically against C-terminal heptad repeat (CHR) region of gp41 protein). No neutralizing activity against any of the viruses tested was observed in purified IgGs from the immunized rabbit sera.

Discussion

The success of passive transfer studies with SHIV infection in macaques and HIV infection in small-animal models and in therapeutic setting in humans suggest that bNAbs have the potential to prevent viral infection [13,64]. Despite these achievements, the field continues to face significant hurdles for the development of an antibody-based vaccine. The approach of reverse vaccinology, by which knowledge of the molecular structure of antigens is built into unnatural immunogens to elicit neutralizing epitopes [65–67], may help overcome some of these roadblocks. Following this approach, several envelope based immunogens have been designed and tested experimentally. These include trimeric soluble gp140 molecules containing the extracellular portion of gp41 coupled with gp120, which have in some cases proven to be immunogenic, but overall have not elicited strong broadly neutralizing responses.

Random mutagenesis has been widely used by researchers to identify beneficial mutations in the absence of structural information, or when such mutations are difficult to predict from protein structure [68]. In the present study we decided to use this strategy for improving the accessibility of the epitopes recognized by selected broadly neutralizing antibodies. This is based on the hypothesis that an envelope with increased affinity for a bNAb will bind more efficiently to the B-cells expressing IgGs with the corresponding specificities thereby improving the clonal expansion of the corresponding B cell clones. Therefore, the selected envelope would be more efficient as an immunogen capable of inducing antibodies against the corresponding envelope region than its wild-type version. In this scenario, long periods of somatic mutation would not be required to increase antibody-epitope affinity for bNAb induction. Furthermore, the identification of HIV-1 infected patients with broadly neutralizing activities
Fig 6. Characterization of the VLPs used for rabbit immunization. VLPs were produced by transfection into 293F cells and VLPs were pelleted from the clarified supernatants. (A) VLPs were analyzed by immunoelectron microscopy labeling with an anti-gp120 antibody, 447-52D. (B) Envelope incorporations in AC10_29 and LR1-C1-VLPs were evaluated by the gp120 and p55 ratios by western blotting in SDS-PAGE gels using 447-52D and p24 (24–4) monoclonal antibodies. (C) Relative Env incorporation into VLPs was calculated by the ratios of gp120 to p55 using phosphorimaging analysis in triplicate. (D) The presence of trimers into AC10_29 and LR1-C1-VLPs and AC10_29 and LR1-C1-virions were analyzed by western
within the first months of infection indicate that long periods of somatic mutation may not always be essential to induce bNAb\[10\].

Here, we have used this approach and successfully selected an envelope variant sequence with increased affinity for the bNAb 4E10 after just one round of selection. The selected envelope (LR1-C1) has an increased affinity for the antibody used as bait (4E10). The amino acid replacements incorporated by this variant, the loss of N-linked glycosylation sites and change in the architecture of the V1/V2 loop, were all consistent with changes that have been previously associated with increased exposure of neutralizing epitopes and which has been linked to increased neutralization sensitivity and increased induction of neutralizing antibodies \[45,46,48–51\]. The increased affinity of several epitopes might also be explained by the selection of an envelope with an open conformation (tier 1-like). This hypothesis would be supported by the observation of an increased binding to 447-52D \[58\]. Additionally, the affinity increases in several epitopes observed could also be due to the 2.7 fold increase in envelope incorporation observed in LR1-C1. Nevertheless, we hypothesize that there is some specificity associated with the affinity increases detected taking into consideration that they do not affect all the epitopes in the same way. In fact, LR1-C1 has a decreased affinity for 2G12 and VRC01. Moreover, we found an association between the 4E10-selected amino acids incorporated in the LR1-C1 variant and increased sensitivity to 4E10 and 2F5 when more than 650 HIV-1 isolates from the Los Alamos database were analysed (674 for 4E10 and 675 for 2F5). Furthermore, in the RV144 vaccine trial efficacy has been associated to non-neutralizing antibodies targeting positions 169 and 181 within the V2 loop that are in close proximity to mutations N160Y and N187D incorporated in our selected envelope \[69\]. The observation that the mutations we have identified in our study and mutations associated to vaccine efficacy in RV144 vaccine trial are proximal may indicate that, this V2 loop region could be a site of vulnerability relevant for induction of antibodies with both neutralizing and antibody-dependent cell-mediated cytotoxic activities. Vaccination strategies based on these immunogens should bear in mind the possible decreased exposure of additional relevant epitopes that could be circumvented by combinations of envelopes with increased exposure of different epitopes.

One aspect that could have limited the success of this method would be associated to a loss of high-affinity clones as a result of the multiple cloning steps required by the selection strategy. An additional limitation would be the low potency of the antibody chosen for selection. Despite all these limitations, our data are consistent and the relevance of improving the exposure of the 4E10 region has been confirmed later thanks to the identification of antibody 10E8, that recognizes the same epitope with greater amplitude and potency \[65\]. In fact, in our study, the 4E10 selected envelope also has an increased affinity for 10E8 antibody (S3 Fig).

Our data are in line with the general belief that extensive glycosylation of the external surface component of Env gp120 contribute importantly to its poor immunogenicity. The gp120 surface glycoproteins of HIV and simian immunodeficiency virus (SIV) each contain approximately 24 sites for N-linked carbohydrate attachment (Asn-X-Ser/Thr). The dispensability of some N-linked glycans for viral replication and the greater sensitivity of some glycan-deficient mutants to antibody-mediated neutralization suggest that these glycans may serve in part as barriers to shield the virus for effective antibody recognition \[38,45,46,48–52,70\]. Additionally, the observation that amino acid replacements associated to increased exposure of 4E10-epitope are associated, not only to an increased sensitivity to the 4E10 antibody, but also to 2F5 are consistent with the proximity of both epitopes in the viral envelope protein. On the other
Selection of an HIV envelope immunogen that directs antibody responses toward the MPER proximal region
hand, the role of variable gp120 loops, particularly the first and second variable loops (V1/V2 region) and the third variable loop (V3) in immunogenicity and antibody evasion have been widely characterized by different groups suggesting that these domains contain epitopes that are targets for neutralizing antibodies and shield different neutralizing epitopes [71–74]. Inherent neutralization resistance of several HIV strains is to a great extent mediated by gp120 V1/V2 domain structure rather than by sequence variations at the target sites. Experimental and cryo-EM structural evidence supported the hypothesis that V1/V2 in one gp120 monomer masks V3 on the same monomer (cis) [75,76].

In this study, the antibody response induced in the mice model by the 4E10-selected envelope variant was enhanced compared to the response induced by the virus carrying the original envelope sequence. Unfortunately, the breadth of the neutralizing response, as well as the mapping of the humoral response induced, could not be assessed due to limitations in sample availability. In order to bypass this limitation, we decided to evaluate the immunogenicity of the 4E10-selected variant in a larger animal model that yield sufficiently large blood samples. However, in that model, animals did not mount a detectable level of neutralization activity. Furthermore, one out of the four rabbits immunized with the 4E10-selected variant redirected antibody response toward a region proximal to the epitope recognized by the antibody used for selection (Fig 8). Moreover, the region to which the antibody response has been redirected

Fig 7. Characterization of the humoral responses induced in immunized rabbits. The humoral immune response of the immunized rabbits was characterized at week 15. (A) The presence of anti-HIV antibodies in rabbit sera were analyzed by western blot. Preimmune sera of rabbit 1640 was also included as an additional negative control. Endpoint ELISA titers to autologous (AC10.29; B) and heterologous (Bal; C) rgp120. Open symbols correspond to animals immunized with no adjuvant. The highest dilution which gave an OD450 2.5 folds higher than pre-immune sera without dilution was designated as the antibody endpoint titer. Results showed data of three independent experiments and results were expressed as the mean ± SD (n = 4). Ns: non significant; “p<0.05 Mann-Whitney U test.

https://doi.org/10.1371/journal.pone.0208345.g007

Fig 8. Characterization of the antibody responses against the V3-loop and the gp41 ectodomain regions. (A) Reactivity of sera from immunized rabbits to the V3 loop was analyzed by ELISA of overlapping 15-mer peptides corresponding to the V3 loop of the AC10_29 isolate. Peptide sequences are shown and the 447-52D epitope is indicated. (B) Reactivity of sera from immunized rabbits to the gp41 ectodomain was analyzed by ELISA of overlapping 15-mer peptides corresponding to the gp41 ectodomain of the AC10_29 isolate and one peptide with the LR1C1 sequence. Peptide sequences are shown and the 4E10 and 2F5 epitopes are also indicated.

https://doi.org/10.1371/journal.pone.0208345.g008
is recognized by 2F5-like antibodies [77]. Possible factors that could explain the absence of neutralizing response include the conformation or the amount of the envelope spikes incorporated into the VLPs and the immunization strategy used, which may not be the most effective approach for the induction of broadly neutralizing antibody responses. In particular, we have generated an envelope variant with potential to better present a specific epitope and, therefore, a potential greater capacity to induce responses directed to the corresponding epitope. For this reason, the immunization strategy chosen included short periods of antigen exposure. However, a longer affinity maturation process may be required with the current prototype [78, 79]. Additionally, there are evidences indicating that gp41 bnAbs are controlled by immune tolerance and require vaccination with regimens designed to transiently dampen immune tolerance [80]. Introduction of mutations that stabilize trimers, enzymatic digestion to remove spikes with aberrant conformation or serial booster vaccination may further help to overcome these limitations [81]. Another way to improve the method would be by selection with quaternary-structure dependent antibodies that would increase the likelihood of selecting variants with intact trimers that would be better inducer of neutralizing antibodies [82, 83].

The results of this study are a proof of concept indicating that the method described here allows us to select, without using any previous structural information, variants with greater exposure of certain epitopes of interest to induce more effective humoral immunity. Moreover, the results shown in here can serve as a starting point for the development of new immunogens through selection with new and possibly multiple different bNAb, the incorporation of successive rounds of selection, or the generation of new libraries from different HIV subtypes. These steps could aid the development of an HIV vaccine through the selection of mutant envelopes and their delivery by incorporation in appropriate vectors. In addition, the present approach could be taken one step further adapting it to the development of immunogens for other viral infections.

Supporting information

S1 Fig. Amplicon design for deep-sequencing of HIV-1 env. Deep-sequencing of the different Env variants was achieved by sequencing of 3 PCR amplicons (Amp_1, Amp_2 and Amp_3) covering regions of interest.

(PPTX)

S2 Fig. Effect of LR1-C1 mutations on viral infectivity. Virus stocks were obtained from the transfection of 293T cells. Stocks were normalized to the amount of p24 and used to infect TZM-bl cells. Luciferase activity (L.U.) was measured as described previously [39].

(TIF)

S3 Fig. Effect of LR1-C1 mutations on affinity for antibody 10E8. Virus stocks were obtained from transfected 293T cells. Increase in 10E8 binding was determined by comparison of the virus captured by the antibody and quantified by p24 when similar amounts of virus (AC10_29 in red and filled circles and LR1-C1 in blue and filled squares) were used as input in a Virion Capture Assay (VCA). Similar amounts of virus suspension with no mAb were used as controls for both viruses (AC10_29 in grey and filled circles and LR1-C1 in grey and filled squares). Statistical analysis was conducted by R using One-way NOVA followed by Newman Keuls post hoc test at each input concentration (**p<0.001 and *p<0.05). Data are represented as mean ± SDEV.

(TIF)

S4 Fig. Prime-boost protocols for mice immunization. Balb/c mice were inoculated at weeks 0 and 2 and bled at week 4. Five animals per group were used. Five prime-boost immunization
protocols were followed. Both groups were inoculated with 100μl of AT-2 inactivated virus at weeks 0 and 2 (2.5μg/ml p24 quantified as explained in the Materials and Methods section) and 100μl of complete Freund adjuvant subcutaneously. Group 1 was inoculated with AC10 AT-2 inactivated virions and group 2 was inoculated with LR1-C1 AT-2 inactivated virions. At week 4, animals were bled by cardiac puncture with anesthesia from both groups. These experiments were performed at BSL3 CReSA Biocontainment Facility with the collaboration of CReSA staff (Barcelona, Spain).

S5 Fig. Prime-boost protocols for immunization of rabbits. Animals were inoculated at weeks 0, 3, 6, 9, 12 and bled at week 15. Four animals per group were used. Five prime-boost immunization protocols were followed. In group 1 (animals from 1640 to 1643) plasmid pcDNA-Gag+pcDNA (250μg/animal each) were boosted twice with dGag VLPs using adjuplex as adjuvant. In group 2 (animals from 1644 to 1647) plasmid pcDNA-Gag+pcDNA-AC10EEO (250μg/boost/animal each) and animals were boosted twice with dGag-AC10 VLPs (20μg of p24/boost/animal) using adjuplex as adjuvant. In group 3 (animals from 1648 to 1651) plasmid pcDNA-Gag+pcDNA-LR1C1EEO (250μg/animal each) and animals were boosted twice with dGag-LR1C1 VLPs using adjuplex as adjuvant. In group 4 (animals from 1652 to 1655) plasmid pcDNA-Gag+pcDNA-AC10EEO (250μg/animal each) and animals were boosted twice with dGag-AC10 VLPs with no adjuvant added. In group 5 (animals from 1656 to 1659) plasmid pcDNA-Gag+pcDNA-LR1C1EEO (250μg/animal each) and animals were boosted twice with dGag-LR1C1 VLPs with no adjuvant added.

S1 Table. Primer sequences used for in vitro random mutagenesis, nested RT-PCR HIV env amplification and sequencing (standard and deep-sequencing).

S2 Table. Neutralization profile of AC10_29 recombinant virus (Clade B, tier 2) used as template for generating the virion library.

S3 Table. Comparison of mutation percentages within the same envelope regions (amplicons) in standard and deep-sequencing before and after selection.

Acknowledgments
The authors do not have any conflict of interests. We wish to thank F. Diez-Fuertes from the AIDS Immunopathology Unit (Instituto de Salud Carlos III, Centro Nacional de Microbiología, Madrid, Spain) for help with the statistical analysis, Dr. R. Wagner from the Institute of Medical Microbiology and Hygiene, Molecular Microbiology (Virology), University Regensburg (Regensburg, Germany) for 96ZM 651_HXB2_V3 SOSIP, Dr. Q. Sattentau from The Sir William Dunn School of Pathology, University of Oxford (Oxford, U. K.) for PGT151 antibody and pNL4-3 plasmid and antibodies 4E10, 2F5, 447-52D, VRC01, 5F3, b12, PG16 and 2G12 were obtained through the NIH AIDS Reagent Program, Division of AIDS, NIAID, NIH.

Author Contributions
Conceptualization: Marc Noguera-Julian, Roger Paredes, Eloisa Yuste, Victor Sanchez-Merino.
Formal analysis: Carolina Beltran-Pavez, Carolina B. Ferreira, Amanda Fabra-Garcia, Maria Casadella, Marc Noguera-Julian, Roger Paredes, Alex Olvera, Christian Brander, Eloisa Yuste, Victor Sanchez-Merino.

Funding acquisition: Roger Paredes, Isabel Haro, Christian Brander, Felipe Garcia, Jose M. Gatell, Eloisa Yuste, Victor Sanchez-Merino.

Investigation: Carolina Beltran-Pavez, Carolina B. Ferreira, Isabel Haro, Christian Brander, Felipe Garcia, Jose M. Gatell, Eloisa Yuste, Victor Sanchez-Merino.

Methodology: Carolina Beltran-Pavez, Carolina B. Ferreira, Alberto Merino-Mansilla, Amanda Fabra-Garcia, Maria Casadella, Marc Noguera-Julian, Alex Olvera, Eloisa Yuste.

Supervision: Eloisa Yuste, Victor Sanchez-Merino.

Writing – original draft: Eloisa Yuste, Victor Sanchez-Merino.

Writing – review & editing: Christian Brander, Eloisa Yuste.

References

1. Wyatt R, Sodroski J. The HIV-1 envelope glycoproteins: fusogens, antigens, and immunogens. Science 1998; 280: 1884–8. PMID: 9632381

2. Mascola JR, Haynes BF. HIV-1 neutralizing antibodies: understanding nature’s pathways. Immunol Rev 2013; 254: 225–44. https://doi.org/10.1111/imr.12075 PMID: 23772623

3. Stamatatos L, Morris L, Burton DR, Mascola JR. Neutralizing antibodies generated during natural HIV-1 infection: good news for an HIV-1 vaccine? Nat Med 2009; 15: 866–70. https://doi.org/10.1038/nm.1949 PMID: 19525964

4. Jaworski JP, Vendrell A, Chiavenna SM Neutralizing Monoclonal Antibodies to Fight HIV-1: On the Threshold of Success. Front Immunol 2016; 7: 661. https://doi.org/10.3389/fimmu.2016.00661 PMID: 28123384

5. Sather DN, Armann J, ChingLK, Mavroniti A, Sellhorn G, Caldwell Z, et al. Factors associated with the development of cross-reactive neutralizing antibodies during human immunodeficiency virus type 1 infection. J Virol. 2009; 83: 757–69. https://doi.org/10.1128/JVI.02036-08 PMID: 18987148

6. Binley JM, Lybarger EA, Crooks ET, Seaman MS, Gray E, Davis KLe et al. Profiling the specificity of neutralizing antibodies in a large panel of plasmas from patients chronically infected with human immunodeficiency virus type 1 subtypes B and C. J Virol. 2008; 82: 11651–68. https://doi.org/10.1128/JVI.01762-08 PMID: 18815292

7. Dhillon AK, Donners H, Pantophlet R, Johnson WE, Decker JM, Shaw GM, et al. Dissecting the neutralizing antibody specificities of broadly neutralizing sera from human immunodeficiency virus type 1-infected donors. J Virol. 2007; 81: 6548–6562. https://doi.org/10.1128/JVI.02749-06 PMID: 17409160

8. Hraber P, Seaman MS, Baier RT, Mascola JR, Montefiori DC, Korber BT Prevalence of broadly neutralizing antibody responses during chronic HIV-1 infection. AIDS.2014; 28: 163–9. https://doi.org/10.1097/QAD.0000000000000106 PMID: 24361768

9. Simonich CA, Williams KL, Verkerke HP, Williams JA, Nduati R, Lee KK et al.J HIV-1 Neutralizing Antibodies with Limited Hypermutation from an Infant. Cell. 2016; 166: 77–87. https://doi.org/10.1016/j.cell.2016.05.055 PMID: 27345369

10. Sanchez-Merino V, Fabra-Garcia A, Gonzalez N, Nicolas D, Merino-Mansilla A, Manzardo C et al. Detection of Broadly Neutralizing Activity within the First Months of HIV-1 Infection. J Virol. 2016; 90: 5231–45. https://doi.org/10.1128/JVI.00049-16 PMID: 26984721

11. Mascola JR, Lewis MG, Stiegler G, Harris D, VanCott TC, Hayes D et al. Protection of Macaques against pathogenic simian/human immunodeficiency virus 89.6PD by passive transfer of neutralizing antibodies. J Virol. 1999; 73: 4009–18. PMID: 10196297

12. Hessell AJ, Rakasz EG, Tehrani DM, Huber M, Weisgrau KL, Landucci G et al. Broadly neutralizing monoclonal antibodies 2F5 and 4E10 directed against the human immunodeficiency virus type 1 gp41 membrane-proximal external region protect against mucosal challenge by simian-human immunodeficiency virus SHIVBa-L. J Virol. 2010; 84: 1302–13. https://doi.org/10.1128/JVI.01272-09 PMID: 19906907
13. Moldt B, Rakasz EG, Schultz N, Chan-Hui PY, Swiderek K, Weisgrau KL, et al. Highly potent HIV-specific antibody neutralization in vitro translates into effective protection against mucosal SHIV challenge in vivo. Proc Natl Acad Sci U S A. 2012; 109: 18921–5. https://doi.org/10.1073/pnas.1214785109 PMID: 23100539

14. Stoddart CA, Galkina SA, Joshi P, Kosikova G, Long BR, Maidji E et al. Efficacy of broadly neutralizing monoclonal antibody PG16 in HIV-infected humanized mice. Virology. 2014; 462–463: 115–25.

15. Horwitz JA, Halper-Stromberg A, Mouquet H, Gittin AD, Tretiakova A, Eisenreich TR et al. HIV-1 suppression and durable control by combining single broadly neutralizing antibodies and antiretroviral drugs in humanized mice. Proc Natl Acad Sci U S A. 2013; 110: 16538–43. https://doi.org/10.1073/pnas.1315259110 PMID: 24043801

16. Gautam R, Nishimura Y, Pegu A, Nason MC, Klein F, Gazumyan A et al. A single injection of anti-HIV-1 antibodies protects against repeated SHIV challenges. Nature; 2016; 533: 105–9. https://doi.org/10.1038/nature17677 PMID: 27120156

17. Shingai M, Donau OK, Plishka RJ, Buckler-White A, Mascola JR, Nabel GJ et al. Passive transfer of modest titers of potent and broadly neutralizing anti-HIV monoclonal antibodies block SHIV infection in macaques. J Exp Med. 2014; 211: 2061–74. https://doi.org/10.1084/jem.20132494 PMID: 25155019

18. Xu L, Pegu A, Rao E, Doria-Rose N, Beninga J, McKee K et al. Trispecific broadly neutralizing HIV antibodies mediate potent SHIV protection in macaques. Science. 2017; 358: 85–90. https://doi.org/10.1126/science.aan630 PMID: 28931639

19. Trkola A, Kuster H, Ruset P, Joos B, Fischer M, Leemann C et al. Delay of HIV-1 rebound after cessation of antiretroviral therapy through passive transfer of human neutralizing antibodies. Nat Med. 2005; 11: 615–22. https://doi.org/10.1038/nm1244 PMID: 15880120

20. Caskey M, Klein F, Lorenzi JC, Seaman MS, West AP Jr., Buckley N et al. Viremia suppressed in HIV-1-infected humans by broadly neutralizing antibody 3BNC117. Nature. 2015

21. Lynch RM, Boritz E, Coates EE, DeZure A, Madden P, Costner P et al. Virologic effects of broadly neutralizing antibody VRC01 administration during chronic HIV-1 infection. Sci Transl Med. 2015; 7: 319ra206. https://doi.org/10.1126/scitranslmed.aad5752 PMID: 26702094

22. Caskey M, Schoofs T, Gruell H, Settler A, Karagounis T, Kreider EF et al. Antibody 10–1074 suppresses viremia in HIV-1-infected individuals. Nat Med. 2017; 23: 185–91. https://doi.org/10.1038/nm.4268 PMID: 28092665

23. Mihaylov MO, Zha L, Cabral-Miranda G, Bachmann MF. Major findings and recent advances in virus-like particle (VLP)-based vaccines. Semin Immunol. 2017; 34: 123–32. https://doi.org/10.1016/j.smim.2017.08.014 PMID: 28887001

24. Zhao C, Ao Z, Yao X Current Advances in Virus-Like Particles as a Vaccination Approach against HIV Infection. Vaccines (Basel). 2016; 4. vaccines4010002 [pii]

25. Pankrac J, Klein K, McKay PF, King DFL, Bain K, Knapp J et al. A heterogeneous human immunodeficiency virus-like particle (VLP) formulation produced by a novel vector system. NPJ Vaccines. 2018; 3: 2. 10.

26. Steichen JM, Kulp DW, Tokatlian T, Escolano A, Dosenovic P, Stanfield RL et al. HIV Vaccine Design to Target Germline Precursors of Glycan-Dependent Broadly Neutralizing Antibodies. Immunity. 2016; 45: 483–96. https://doi.org/10.1016/j.immuni.2016.08.016 PMID: 27617678

27. You L, Arnold FH Directed evolution of subtilisin E in Bacillus subtilis to enhance total activity in aqueous dimethylformamide. Protein Eng. 1996; 9: 77–83. PMID: 9053906

28. Cherry JR, Lamasa MH, Schneider P, Vind J, Svendsen A, Jones A et al. Directed evolution of a fungal peroxidase. Nat Biotechnol. 1999; 17: 379–84. https://doi.org/10.1038/7939 PMID: 10207888

29. Kim S, Kim YC, Qi H, Su K, Morrison SL, Chow SA. Efficient identification of human immunodeficiency virus type 1 mutants resistant to a protease inhibitor by using a random mutant library. Antimicrob Agents Chemother. 2011; 55: 5090–9. https://doi.org/10.1128/AAC.00687-11 PMID: 21876045

30. Wei X, Decker JM, Liu H, Zhang Z, Arani RB, Kilby JM et al. Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy. Antimicrob Agents Chemother. 2002; 46: 1896–905. https://doi.org/10.1128/AAC.46.6.1896-1905.2002 PMID: 12019106

31. Yoon H, Macke J, West AP Jr., Foley B, Bjorkman PJ, Korber B et al. CATNAP: a tool to compile, analyze and tally neutralizing antibody panels. Nucleic Acids Res. 2015; 43: W213–W219. https://doi.org/10.1093/nar/gkv404 PMID: 26044712

32. Mothe B, Hu X, Llano A, Rosati M, Olivera A, Kulkarni V et al. A human immune data-informed vaccine concept elicits strong and broad T-cell specificities associated with HIV-1 control in mice and macaques. J Transl Med. 2015; 13: 60. https://doi.org/10.1186/s12967-015-0392-5 PMID: 25879820

33. Llano A, Carrillo J, Mothe B, Ruiz L, Marfil S, Garcia E et al. Expansion of antibody secreting cells and modulation of neutralizing antibody activity in HIV infected individuals undergoing structured treatment
Selection of an HIV envelope immunogen that directs antibody responses toward the MPER proximal region

34. Alvarez-Fernandez C, Crespo GA, Garcia-Perez J, Garcia F, Blanco J, Escriba-Garcia L et al. Generation and characterization of a defective HIV-1 Virus as an immunogen for a therapeutic vaccine. PLoS One. 2012; 7: e48848. https://doi.org/10.1371/journal.pone.0048848 PMID: 23144996

35. Lynch A, Meyers AE, Williamson AL, Rybicki EP Stability studies of HIV-1 Pr55gag virus-like particles made in insect cells after storage in various formulation media. Virol J. 2012; 9: 210. 1743-422X-9-210 [pii]; https://doi.org/10.1186/1743-422X-9-210 PMID: 22888963

36. Yuste E, Reeves JD, Doms RW, Desrosiers RC Modulation of Env content in virions of simian immunodeficiency virus: correlation with cell surface expression and virion infectivity. J Virol. 2004; 78: 6775–85. https://doi.org/10.1128/JVI.78.13.6775-6785.2004 PMID: 15194752

37. Cale EM, Gorman J, Radakovich NA, Crooks ET, Osoawa K, Tong T et al. Virus-like Particles Identify an HIV V1V2 Apex-Binding Neutralizing Antibody that Lacks a Protruding Loop. Immunity. 2017; 46: 777–91. https://doi.org/10.1016/j.immuni.2017.04.011 PMID: 28514685

38. Yuste E, Bixby J, Lifson J, Sato S, Johnson W, Desrosiers R Glycosylation of gp41 of simian immunodeficiency virus shields epitopes that can be targets for neutralizing antibodies. J Virol. 2008; 82: 12472–86. https://doi.org/10.1128/JVI.01382-08 PMID: 18829751

39. Medina-Ramirez M, Sanchez-Merino V, Sanchez-Palomino S, Merino-Mansilla A, Ferreirra CB, Perez I et al. Broadly cross-neutralizing antibodies in HIV-1 patients with undetectable viremia. J Virol. 2011; 85: 5804–13. https://doi.org/10.1128/JVI.02482-10 PMID: 21471239

40. Binley JM, Wrin T, Korber B, Zwick MB, Wang M, Chappey C, Stiegler G, Kunert R, Sato S, Johnson W, Desrosiers R Glycosylation of gp41 of simian immunodeficiency virus type 1 monoclonal antibodies. J Virol 78: 13232–13252. https://doi.org/10.1128/JVI.78.23.13232-13252.2004 PMID: 15542675

41. Li M, Gao F, Mascola JR, Stamatatos L, Polonis VR, Koutsoukos M et al. Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicted neutralizing antibodies. J Virol. 2005; 79: 10108–25. https://doi.org/10.1128/JVI.79.16.10108-10125.2005 PMID: 16051804

42. Montefiori DC, Roederer M, Morris L, Seaman MS Neutralization tiers of HIV-1. Curr Opin HIV AIDS. 2013; 18: 128–36. https://doi.org/10.1097/COH.0b013e32835f0b0f PMID: 29266013

43. Buzon MJ, Codoner FM, Frost SD, Pou C, Puertas MC, Massanella M et al. Deep molecular characterization of HIV-1 dynamics under suppressive HAART. PLoS Pathog. 2011; 7: e1002314. https://doi.org/10.1371/journal.ppat.1002314 PMID: 22046128

44. Feng DF, Johnson MS, Doolittle RF. Aligning amino acid sequences: comparison of commonly used methods. J Mol Evol. 1984; 21: 112–25. PMID: 6100188

45. Bolmstedt A, Sjolander S, Hansen JE, Akerblom L, Hemming A, Hu SL et al. Influence of N-linked glycans in V4-V5 region of human immunodeficiency virus type 1 glycoprotein gp160 on induction of a virus-neutralizing humoral response. J Acquir Immune Defic Syndr Hum Retrovirol. 1996; 12: 213–20. PMID: 8673525

46. Gram GJ, Hemming A, Bolmstedt A, Jansson B, Olofsson S, Akerblom L et al. Identification of an N-linked glycan in the V1-loop of HIV-1 gp120 influencing neutralization by anti-V3 antibodies and soluble CD4. Arch Virol. 1994; 139: 253–61. PMID: 7832633

47. Johnson WE, Morgan J, Reitter J, Puffer BA, Czajak S, Doms RW et al. A replication-competent, neutralization-sensitive variant of simian immunodeficiency virus lacking 100 amino acids of envelope. J Virol. 2002; 76: 2075–86. PMID: 11836385

48. Kolchinsky P, Kripilov E, Bartley P, Rubinstein R, Sodroski J (2001) Loss of a single N-linked glycan allows CD4-independent human immunodeficiency virus type 1 infection by altering the position of the gp120 V1/V2 variable loops. J Virol 75: 3435–3443. https://doi.org/10.1128/JVI.75.7.3435-3443.2001 PMID: 11238869

49. Ly A, Stamatatos L. V2 loop glycosylation of the human immunodeficiency virus type 1 SF162 envelope facilitates interaction of this protein with CD4 and CCR5 receptors and protects the virus from neutralization by anti-V3 loop and anti-CD4 binding site antibodies. J Virol. 2000; 74: 6769–76. PMID: 10888615

50. McCaffrey RA, Saunders C, Hensel M, Stamatatos L. N-linked glycosylation of the V3 loop and the immunologically silent face of gp120 protects human immunodeficiency virus type 1 SF162 from neutralization by anti-gp120 and anti-gp41 antibodies. J Virol. 2004; 78: 3279–86. https://doi.org/10.1128/JVI.78.7.3279-3285.2004 PMID: 15016849

51. Reitter JN, Desrosiers RC Identification of replication-competent strains of simian immunodeficiency virus lacking multiple attachment sites for N-linked carbohydrates in variable regions 1 and 2 of the surface envelope protein. J Virol. 1998; 72: 5399–407. PMID: 9620994
52. Schonning K, Jansson B, Olofsson S, Nielsen JO, Hansen JS. Resistance to V3-directed neutralization caused by an N-linked oligosaccharide depends on the quaternary structure of the HIV-1 envelope oligomer. Virology. 1996; 218: 134–40. PMID: 8615015

53. Cao J, Sullivan N, Desjardins E, Parolin C, Robinson J, Wyatt R et al. Replication and neutralization of human immunodeficiency virus type 1 lacking the V1 and V2 variable loops of the gp120 envelope glycoprotein. J Virol. 1997; 71: 9808–12. PMID: 9371651

54. Pinter A, Honnen WJ, He Y, Gorny MK, Zolla-Pazner S, Kayman SC. The V1/V2 domain of gp120 is a global regulator of the sensitivity of primary human immunodeficiency virus type 1 isolates to neutralization by antibodies commonly induced upon infection. J Virol. 2004; 78: 5205–15. https://doi.org/10.1128/JVI.78.10.5205-5215.2004 PMID: 15113902

55. Krachmanov C, Pinter A, Honnen WJ, Gorny MK, Nyambi PN, Zolla-Pazner S, et al. Antibodies that are cross-reactive for human immunodeficiency virus type 1 clade a and clade B v3 domains are common in patient sera from Cameroone, but their neutralization activity is usually restricted by epitope masking. J Virol. 2005; 79: 780–90. https://doi.org/10.1128/JVI.79.2.780-790.2005 PMID: 15613306

56. Krachmanov CP, Honnen WJ, Kayman SC, Gorny MK, Zolla-Pazner S, Pinter A Factors determining the breadth and potency of neutralization by V3-specific human monoclonal antibodies derived from subjects infected with clade A or clade B strains of human immunodeficiency virus type 1. J Virol. 2006; 80: 7127–32. https://doi.org/10.1128/JVI.02619-05 PMID: 16809318

57. Liu L, Cimbro R, Russo P, Berger EA. Intraprotomer masking of third variable loop (V3) epitopes by the first and second variable loops (V1/V2) within the native HIV-1 envelope glycoprotein trimer. Proc Natl Acad Sci U S A. 2011; 108: 20148–53. https://doi.org/10.1073/pnas.110484109 PMID: 21288330

58. Seaman MS, Janes H, Hawkins N, Grandpre LE, Devoy C, Giri A et al. Tiered categorization of a diverse panel of HIV-1 Env pseudoviruses for assessment of neutralizing antibodies. J Virol. 2010; 84: 1439–52. https://doi.org/10.1128/JVI.02108-09 PMID: 19939925

59. Doores KJ, Burton DR. Variable loop glycan dependency of the broad and potent HIV-1-neutralizing antibodies PG9 and PG16. J Virol. 2010; 84: 10510–21. https://doi.org/10.1128/JVI.00552-10 PMID: 20686044

60. Blattner C, Lee JH, Sliepen K, Derking R, Falkowska E, de la Pena AT et al. Structural delineation of a quaternary, cleavage-dependent epitope at the gp41-gp120 interface on intact HIV-1 Env trimers. Immunity. 2014; 40: 669–80. https://doi.org/10.1016/j.immuni.2014.04.008 PMID: 24768548

61. Turpin JA, Terpening SJ, Schaeffer CA, Yu G, Glover CJ, Felsted RL et al. Inhibitors of human immunodeficiency virus type 1 zinc fingers prevent normal processing of gag precursors and result in the release of noninfectious virus particles. J Virol. 1996; 70: 6180–89. PMID: 8709244

62. Rossio JL, Esser MT, Suryanarayana K, Schneider DK, Bess JW Jr., Vasquez GM et al. Inactivation of human immunodeficiency virus type 1 infectivity with preservation of conformational and functional integrity of virion surface proteins. J Virol. 1998; 72: 7992–8001. PMID: 9733838

63. Postler TS, Desrosiers RC. The tale of the long tail: the cytoplasmic domain of HIV-1 gp41. J Virol. 2013; 87: 2–15. https://doi.org/10.1128/JVI.02053-12 PMID: 23077317

64. Balazs AB, Chen J, Hong CM, Rao DS, Yang L, Baltimore D. Antibody-based protection against HIV infection by vectored immunoprophylaxis. Nature. 2012; 481: 81–4.

65. Koff WC, Burton DR, Johnson PR, Walker BD, King CR, Nabel GJ et al.) Accelerating next-generation vaccine development for global disease prevention. Science. 2013; 340: 1232910. https://doi.org/10.1126/science.1232910 PMID: 23723240

66. Nabel GJ Designing tomorrow’s vaccines. N Engl J Med. 2013; 365: 551–560. https://doi.org/10.1056/NEJMr1204186 PMID: 23388006

67. Wu X, Yang ZY, Li Y, Hogerkorp CM, Schief WR, Seaman MS et al. Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1. Science. 2010; 329: 856–61. https://doi.org/10.1126/science.1187695 PMID: 20616233

68. Daugherty PS, Chen G, Iverson BL, Georgiou G Quantitative analysis of the effect of the mutation frequency on the affinity maturation of single chain Fv antibodies. Proc Natl Acad Sci U S A. 2000; 97: 2209–34. https://doi.org/10.1073/pnas.030527597 PMID: 10688877

69. Rolland M, Edelfson PT, Larsen BB, Tovanabutra S, Sanders-Buell E, Hertz T. et al. Increased HIV-1 vaccine efficacy against viruses with genetic signatures in Env V2. Nature. 2012; 490: 417–20. https://doi.org/10.1038/nature11519 PMID: 22960785

70. Wang W, Nie J, Prochnow C, Truong C, Jia Z, Wang S et al. A systematic study of the N-glycosylation sites of HIV-1 envelope protein on infectivity and antibody-mediated neutralization. Retrovirology. 2013; 10: 14. https://doi.org/10.1186/1742-4690-10-14 PMID: 23384254

71. Bunnik EM, Euler Z, Welkers MR, Boeser-Nunnink BD, Gijsen JM, Prins JM et al. Adaptation of HIV-1 envelope gp120 to humoral immunity at a population level. Nat Med. 2010; 16: 995–7. https://doi.org/10.1038/nm.2203 PMID: 20802498
72. Bunnik EM, Pisal S, van Nuenen AC, Schuitmaker H. Autologous neutralizing humoral immunity and evolution of the viral envelope in the course of subtype B human immunodeficiency virus type 1 infection. J Virol. 2008; 82: 7932–41. https://doi.org/10.1128/JVI.00757-08 PMID: 18524815

73. Rong R, Bibollet-Ruche F, Mulenga J, Allen S, Blackwell JL, Derdeyn CA. Role of V1V2 and other human immunodeficiency virus type 1 envelope domains in resistance to autologous neutralization during clade C infection. J Virol. 2007; 81: 1350–9. https://doi.org/10.1128/JVI.01839-06 PMID: 17079307

74. Sagar M, Wu X, Lee S, Overbaugh J. Human immunodeficiency virus type 1 V1-V2 envelope loop sequences expand and add glycosylation sites over the course of infection, and these modifications affect antibody neutralization sensitivity. J Virol. 2006; 80: 9586–98. https://doi.org/10.1128/JVI.00141-06 PMID: 16973562

75. Haynes BF, Gilbert PB, McElrath MJ, Zolla-Pazner S, Tomaras GD, Alam SM, et al. Immune-correlates analysis of an HIV-1 vaccine efficacy trial. N Engl J Med. 2012; 366: 1275–1286. https://doi.org/10.1056/NEJMoai1113425 PMID: 22475592

76. Lyumkis D, Julien JP, de VN, Cupo A, Potter CS, Klasse PJ, et al. Cryo-EM structure of a fully glycosylated soluble cleaved HIV-1 envelope trimer. Science. 2013; 342: 1484–90. https://doi.org/10.1126/science.1245627 PMID: 24179160

77. Li D, Liu J, Zhang L, Xu T, Chen J, Wang L et al. N-terminal residues of an HIV-1 gp41 membrane-proximal external region antigen influence broadly neutralizing 2F5-like antibodies. Virol Sin. 2015; 30: 449–56. https://doi.org/10.1007/s12250-015-3664-6 PMID: 26715302

78. Tiller T, Tsuji M, Yurasov S, Velinzon K, Nussenzweig MC, Wardemann H. Autoreactivity in human IgG+ memory B cells. Immunity. 2007; 26: 205–13. https://doi.org/10.1016/j.immuni.2007.01.009 PMID: 17306569

79. Scheid JF, Mouquet H, Feldhahn N, Seaman MS, Velinzon K, Pietzsch J, et al. Broad diversity of neutralizing antibodies isolated from memory B cells in HIV-infected individuals. Nature. 2009; 458: 636–40. https://doi.org/10.1038/nature07930 PMID: 19287373

80. Zhang R, Verkoczy L, Wiehe K, Munir AS, Nicely NI, Santra S, et al. Initiation of immune tolerance-controlled HIV gp41 neutralizing B cell lineages. Sci Transl Med. 2016; 8: 336ra62. https://doi.org/10.1126/scitranslmed.aaf0618 PMID: 27122615

81. Lavinder JJ, Hoi KH, Reddy ST, Wine Y, Georgiou G Systematic Characterization and Comparative Analysis of the Rabbit Immunoglobulin Repertoire. PLoS One. 2014; 9: e101322. https://doi.org/10.1371/journal.pone.0101322 PMID: 24978027

82. Sanders RW, van Gils MJ, Derking R, Sok D, Ketas TJ, Burger JA et al. HIV-1 VACCINES. HIV-1 neutralizing antibodies induced by native-like envelope trimers. Science. 2015; 349: aac4223. https://doi.org/10.1126/science.aac4223 PMID: 26089353

83. Saunders KO, Verkoczy LK, Jiang C, Zhang J, Parks R, Chen H et al. Vaccine Induction of Heterologous Tier 2 HIV-1 Neutralizing Antibodies in Animal Models. Cell Rep. 2017; 21: 3681–90. https://doi.org/10.1016/j.celrep.2017.12.028 PMID: 29281818